Microalgal Fucoxanthin in Environmental Medicine: Sustainable Bioproduction, Bioavailability Enhancement, and Translational Health Applications
International Journal of Environmental Medicine · 09.11.2026 · 1 (4) · 19
DOI: 10.3390/ijem1040019 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Environmental Medicine, online erschienen am 09.11.2026. Verfasst von Claudio Guajardo-Barbosa und 4 weiteren Autor:innen. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Microalgal fucoxanthin is a marine xanthophyll relevant to environmental medicine because it links sustainable resource recovery with prevention-oriented research on environmentally driven metabolic disorders.
Methods
This critical narrative review synthesizes recent peer-reviewed studies, related reviews, and regulatory documents on fucoxanthin chemistry, microalgal sources, cultivation, downstream processing, bioavailability enhancement, safety, and translational evidence.
Findings
Diatoms and haptophytes, including Phaeodactylum tricornutum, Tisochrysis lutea, Isochrysis galbana, Nitzschia laevis, Cyclotella meneghiniana, and Conticribra weissflogii, are candidate production platforms, while Poterioochromonas malhamensis currently lacks the safety and regulatory evidence required for food use. Evidence for metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, diabetes, inflammation, lipid metabolism, microbiota modulation, and chemoprevention remains predominantly preclinical or is derived from macroalgal or combined marine formulations. No randomized clinical trial evaluating a standardized microalgal fucoxanthin formulation with pharmacokinetic characterization was identified in the literature reviewed. Wastewater-derived biomass faces a strict regulatory barrier to oral human use and is currently best suited to environmental and agricultural applications unless contaminant clearance and product-specific safety are demonstrated.
Conclusions
Bioavailability is constrained by instability, poor aqueous dispersibility, intestinal de-esterification to fucoxanthinol, and hepatic oxidation to amarouciaxanthin A, but encapsulation and lipid-matrix systems are promising. Translation requires authenticated strains, human-grade cultivation, validated processing, product-specific toxicology, regulatory dossiers, and controlled clinical studies.
Zitieren
APA
Guajardo-Barbosa, C., Quiñones-Gutiérrez, Y., López-Chuken, U. J., Barrón-González, M. P., & Beltrán-Rocha, J. C. (2026). Microalgal Fucoxanthin in Environmental Medicine: Sustainable Bioproduction, Bioavailability Enhancement, and Translational Health Applications. International Journal of Environmental Medicine, 1(4), 19. https://doi.org/10.3390/ijem1040019
Vancouver
Guajardo-Barbosa C, Quiñones-Gutiérrez Y, López-Chuken UJ, Barrón-González MP, Beltrán-Rocha JC. Microalgal Fucoxanthin in Environmental Medicine: Sustainable Bioproduction, Bioavailability Enhancement, and Translational Health Applications. International Journal of Environmental Medicine. 2026;1(4):19. doi:10.3390/ijem1040019
BibTeX
@article{GuajardoBarbosa2026,
author = {Guajardo-Barbosa, Claudio and Quiñones-Gutiérrez, Yadira and López-Chuken, Ulrico Javier and Barrón-González, María Porfiria and Beltrán-Rocha, Julio César},
title = {Microalgal Fucoxanthin in Environmental Medicine: Sustainable Bioproduction, Bioavailability Enhancement, and Translational Health Applications},
journal = {International Journal of Environmental Medicine},
year = {2026},
volume = {1},
number = {4},
pages = {19},
doi = {10.3390/ijem1040019}
}
EUVIMED